Bank of America’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-25,721
| Closed | -$40.9K | – | 8575 |
|
|
2024
Q1 | $40.9K | Sell |
25,721
-31,241
| -55% | -$46.3K | ﹤0.01% | 6579 |
|
|
2023
Q4 | $48.9K | Sell |
56,962
-54,543
| -49% | -$47.9K | ﹤0.01% | 6602 |
|
|
2023
Q3 | $119K | Buy |
111,505
+1,652
| +2% | +$3.42K | ﹤0.01% | 6174 |
|
|
2023
Q2 | $285K | Buy |
109,853
+25,817
| +31% | +$92.1K | ﹤0.01% | 5611 |
|
|
2023
Q1 | $343K | Buy |
84,036
+29,529
| +54% | +$136K | ﹤0.01% | 5621 |
|
|
2022
Q4 | $274K | Buy |
54,507
+13,773
| +34% | +$86.3K | ﹤0.01% | 5751 |
|
|
2022
Q3 | $533K | Sell |
40,734
-100,148
| -71% | -$1.52M | ﹤0.01% | 5345 |
|
|
2022
Q2 | $1.81M | Buy |
140,882
+100,100
| +245% | +$1.39M | ﹤0.01% | 4398 |
|
|
2022
Q1 | $622K | Sell |
40,782
-5,204
| -11% | -$81.2K | ﹤0.01% | 5664 |
|
|
2021
Q4 | $814K | Buy |
45,986
+12,961
| +39% | +$249K | ﹤0.01% | 5466 |
|
|
2021
Q3 | $695K | Buy |
33,025
+20,283
| +159% | +$447K | ﹤0.01% | 5382 |
|
|
2021
Q2 | $251K | Buy |
12,742
+5,619
| +79% | +$132K | ﹤0.01% | 5941 |
|
|
2021
Q1 | $207K | Buy |
7,123
+797
| +13% | +$22.3K | ﹤0.01% | 6016 |
|
|
2020
Q4 | $191K | Sell |
6,326
-64,235
| -91% | -$1.41M | ﹤0.01% | 5631 |
|
|
2020
Q3 | $1.12M | Buy |
70,561
+56,608
| +406% | +$1.03M | ﹤0.01% | 4127 |
|
|
2020
Q2 | $275K | Buy |
13,953
+8,058
| +137% | +$154K | ﹤0.01% | 5032 |
|
|
2020
Q1 | $73K | Sell |
5,895
-9,866
| -63% | -$161K | ﹤0.01% | 5696 |
|
|
2019
Q4 | $291K | Buy |
15,761
+13,832
| +717% | +$202K | ﹤0.01% | 5390 |
|
|
2019
Q3 | $27K | Buy |
1,929
+594
| +44% | +$8.91K | ﹤0.01% | 6521 |
|
|
2019
Q2 | $20K | Buy |
+1,335
| New | +$19.5K | ﹤0.01% | 6574 |
|
Bank of America's NGM Position: Q2 2024 in Review
Bank of America sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 25,721 shares — an estimated $40.9K sold.
Bank of America first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $1.81M in Q2 2022. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Bank of America reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Bank of America sold 25,721 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $40.9K.
- Bank of America first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Bank of America's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $1.81M in Q2 2022.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Bank of America's 13F filing for Q2 2024, filed 14 Aug 2024.